Evidence map›Paper›PMID 40264659›Full record

ArticleFrontiers in pharmacology2025

Brosimine B and the biphasic dose-response: insights into hormesis and retinal neuroprotection.

Susanne Suely Santos Fonseca, Natacha M S Port's, Gisele Priscila Soares Aguiar, Eliã P Botelho, Nádia M G Couto, Wandson Braamcamp Souza Pinheiro, André Salim Khayat, Elizabeth S Yamada, Edmar T Costa, Chubert Bernardo C Sena and 3 more

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Susanne Suely Santos FonsecaInstitute of Technology, Federal University of Pará, Belém, Pará, Brazil.
Natacha M S Port'sLaboratory of Neuroplasticity, Institute of Health Sciences, Federal University of Pará, Belém, Pará, Brazil.
Gisele Priscila Soares AguiarLaboratory of Neuroplasticity, Institute of Health Sciences, Federal University of Pará, Belém, Pará, Brazil.
Eliã P BotelhoLaboratory of Neuroplasticity, Institute of Health Sciences, Federal University of Pará, Belém, Pará, Brazil.
Nádia M G CoutoCentral Extraction Laboratory, Federal University of Pará, Belém, Pará, Brazil.
Wandson Braamcamp Souza PinheiroCentral Extraction Laboratory, Federal University of Pará, Belém, Pará, Brazil.
André Salim KhayatOncology Research Center, Hospital University João of Barros Barreto, Federal University of Pará, Belém, Pará, Brazil.
Elizabeth S YamadaLaboratory of Experimental Neuropathology, Hospital University João of Barros Barreto, Federal University of Pará, Belém, Pará, Brazil.
Edmar T CostaLaboratory of Experimental Neuropathology, Hospital University João of Barros Barreto, Federal University of Pará, Belém, Pará, Brazil.
Chubert Bernardo C SenaLaboratory of Structural Biology, Federal University of Pará, Belém, Pará, Brazil.
Mara Silvia P ArrudaCentral Extraction Laboratory, Federal University of Pará, Belém, Pará, Brazil.
Carlomagno P BahiaLaboratory of Neuroplasticity, Institute of Health Sciences, Federal University of Pará, Belém, Pará, Brazil.
Antonio PereiraInstitute of Technology, Federal University of Pará, Belém, Pará, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The biphasic dose-response behavior, also known as hormesis, is a characteristic feature of numerous natural products. It is defined by beneficial effects at low concentrations and toxicity at higher doses. This study investigates the hormetic effects of Brosimine B, a flavonoid derived from Brosimum acutifolium, on retinal cell viability under oxidative stress. Methods: To simulate ischemic conditions, we used an oxygen-glucose deprivation (OGD) model. Retinal cells were treated with varying concentrations of Brosimine B, and analyses of cell viability, reactive oxygen species (ROS) production, and antioxidant enzyme activity were performed. Results: Brosimine B at 10 µM significantly enhanced cell viability and reduced ROS production, likely through modulation of oxidative stress-protective enzymes such as catalase. However, higher concentrations (>10 µM) induced cytotoxic effects. A computational modeling approach using a hormetic (inverted U-shaped) model revealed biologically interpretable parameters, including a peak response at 10.2 µM and a hormetic zone width (σ = 6.5 µM) (R Discussion: These results confirm that Brosimine B exhibits hormetic neuroprotective effects within a well-defined concentration window, supporting its potential as a therapeutic agent for oxidative stress-related retinal damage. The study highlights the value of computational modeling in optimizing dose-response analyses, offering a framework for refining natural product therapies and predicting toxicological thresholds in pharmacological applications.

Indexed as

antioxidantBrosimine bhormesisnatural productsneuroprotectionoxidative stressretinal cell

Identifiers

PMID40264659
PMCPMC12012618

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.